Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

Nissen, Steven E., Lincoff, A. Michael, Brennan, Danielle, Ray, Kausik K., Mason, Denise, Kastelein, John J.P., Thompson, Paul D., Libby, Peter, Cho, Leslie, Plutzky, Jorge, Bays, Harold E., Moriarty, Patrick M., Menon, Venu, Grobbee, Diederick E., Louie, Michael J., Chen, Chien-Feng, Li, Na, Bloedon, LeAnne, Robinson, Paula, Horner, Maggie, Sasiela, William J., McCluskey, Jackie, Davey, Deborah, Fajardo-Campos, Pedro, Petrovic, Predrag, Fedacko, Jan, Zmuda, Witold, Lukyanov, Yury, Nicholls, Stephen J.·2023·New England Journal of Medicine
DOI 10.1056/nejmoa2215024

Cited by (1,000)

Items 101–200 of 1,000

  1. Dietary fat quality, plasma atherogenic lipoproteins, and atherosclerotic cardiovascular disease: An overview of the rationale for dietary recommendations for fat intake
    Jacob Juel Christensen, Erik Arnesen, Amanda Rundblad, Vibeke H. Telle‐Hansen, Ingunn Narverud, Rune Blomhoff, Martin Prøven Bogsrud, Kjetil Retterstøl, Stine Marie Ulven, Kirsten Bjørklund Holven · 2023 · Atherosclerosis
  2. Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma
    Huina Wang, Xiuli Yi, Xiangxu Wang, Yuqi Yang, Hengxiang Zhang, Hao Wang, Jianru Chen, Baolu Zhang, Sen Guo, Lili Wu et al. · 2024 · Cell Reports
  3. Expert opinion on the integration of combination therapy into the treatment algorithm for the management of dyslipidaemia: the integration of ezetimibe and bempedoic acid may enhance goal attainment
    Klaus Georg Parhofer, Carlos Aguíar, Maciej Banach, Heinz Drexel, Ioanna Gouni‐Berthold, Leopoldo Pérez de Isla, Ernst R. Rietzschel, Alberto Zambon, Kausik Kumar Ray · 2025 · European Heart Journal - Cardiovascular Pharmacotherapy
  4. Cardiovascular risk factors management in older adults: a clinical consensus statement from the European Association of Preventive Cardiology of the ESC and the ESC Council for Cardiology Practice
    Roberto F.E. Pedretti, Riccardo Asteggiano, Andreas B. Gevaert, Thomas Scott Bowen, Stefano Caselli, Véronique Cornelissen, Ruxandra Christodorescu, Giuseppe Derosa, François Diévart, Donata Kurpas et al. · 2025 · European Journal of Preventive Cardiology
  5. Potential therapeutic strategies for MASH: from preclinical to clinical development
    Zhifu Xie, Yufeng Li, Long Cheng, Yidan Huang, Wanglin Rao, Honglu Shi, Jingya Li · 2024 · Life Metabolism
  6. The clinical relevance of the reversal of coronary atherosclerotic plaque
    Arturo Cesaro, Vincenzo Acerbo, Ciro Indolfi, Pasquale Perrone Filardi, Paolo Calabrò · 2024 · European Journal of Internal Medicine
  7. The prevention and management of chronic kidney disease among patients with metabolic syndrome
    Doreen Zhu, Parminder K. Judge, Christoph Wanner, Richard Haynes, William Guy Herrington · 2025 · Kidney International
  8. Recent Advances in Targeted Management of Inflammation In Atherosclerosis: A Narrative Review
    Rafael Zubirán, Edward B. Neufeld, Amaury Dasseux, Alan Thomas Remaley, Alexander V. Sorokin · 2024 · Cardiology and Therapy
  9. Drugs for dyslipidaemia: the legacy effect of the Scandinavian Simvastatin Survival Study (4S)
    Timo E. Strandberg, Petri T. Kovanen, Donald M. Lloyd‐Jones, Frederick Johan Raal, Raul Dias Santos, Gerald Francis Watts · 2024 · The Lancet
  10. Triglycerides revisited: is hypertriglyceridaemia a necessary therapeutic target in cardiovascular disease?
    Heinz Drexel, Juan Luis Tamargo, Juan Carlos Kaski, Basil S. Lewis, Christoph H. Saely, Peter Fraunberger, Dobromir Dobrev, Maki Komiyama, THOMAS PLATTNER, Stefan Agewall et al. · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
  11. The Hurdle of Access to Emerging Therapies and Potential Solutions in the Management of Dyslipidemias
    Brett Stephen Mansfield, Farzahna Mohamed, Miriam Larouche, Frederick Johan Raal · 2024 · Journal of Clinical Medicine
  12. Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence
    Alfredo Mauriello, Adriana Correra, Anna Chiara Maratea, Alfredo Caturano, Biagio Liccardo, Marco Alfonso Perrone, Antonio Giordano, Gerardo Nigro, Antonello D’Andrea, Vincenzo Russo · 2025 · Journal of Clinical Medicine
  13. Landscape of Statin as a Cornerstone in Atherosclerotic Cardiovascular Disease
    Cheng Yang, Yongjian Wu, Jie Qian, Jian‐Jun Li · 2023 · Reviews in Cardiovascular Medicine
  14. CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
    Oliver Schnell, Katharine D. Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández‐Fernández, Thomas M. Forst, Juan P. Frías, James R. Gavin, Francesco Giorgino et al. · 2024 · Cardiovascular Diabetology
  15. Bayesian Analytical Methods in Cardiovascular Clinical Trials: Why, When, and How
    Samuel Heuts, Michal J. Kawczynski, Ahmed Sayed, Sarah Urbut, Arthur M. Albuquerque, John M. Mandrola, Sanjay Kaul, Frank E. Harrell, Andrea Gabrio, James M. Brophy · 2024 · Canadian Journal of Cardiology
  16. The role of systemic inflammation in remnant cholesterol-associated cardiovascular risk: insights from the EPIC-Norfolk study
    Jordan M Kraaijenhof, Marije Kerkvliet, Nick S. Nurmohamed, Aldo Grefhorst, Jeffrey Kroon, Nicholas J. Wareham, G. Kees Hovingh, Erik S.G. Stroes, S. Matthijs Boekholdt, Laurens F. Reeskamp · 2025 · European Journal of Preventive Cardiology
  17. The Role of Non-HDL Cholesterol and Apolipoprotein B in Cardiovascular Disease: A Comprehensive Review
    Vasiliki K. Katsi, Nikolaos Argyriou, Christos Fragoulis, Konstantinos P Tsioufis · 2025 · Journal of Cardiovascular Development and Disease
  18. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias - 2023
    Niki Katsiki, Theodosios D. Filippatos, Charalambos V. Vlachopoulos, Demosthenis B Panagiotakos, Haralampos J. Milionis, Alexandros D. Tselepis, Anastasia Garoufi, Lοukianos S. Rallidis, Dimitrios J. Richter, Tzortzis Nomikos et al. · 2024 · Atherosclerosis Plus
  19. Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease
    Xi Li, Zhi-Fan Li, Na‐Qiong Wu · 2025 · Reviews in Cardiovascular Medicine
  20. Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk
    Panagiotis Theofilis, Panayotis K. Vlachakis, Paschalis Karakasis, Rigas Kalaitzidis · 2025 · Current Atherosclerosis Reports
  21. Emerging Therapies for the Treatment of Atherosclerotic Cardiovascular Disease: From Bench to Bedside
    Marko Kumrić, Hrvoje Urlić, Joško Božić, Marino Vilović, Tina Tičinović Kurir, Duška Glavaš, Dino Miric, Jakša Zanchi, Anteo Bradarić, Mislav Lozo et al. · 2023 · International Journal of Molecular Sciences
  22. Dyslipidemia: A Narrative Review on Pharmacotherapy
    Lucas Dorneles de Oliveira, Arthur Cicupira Rodrigues de Assis, Viviane Zorzanelli Rocha Giraldez, Thiago Luis Scudeler, Paulo Rogério Soares · 2024 · Pharmaceuticals
  23. Clinical practice guideline for the management of lipids in adults with diabetic kidney disease: abbreviated summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2024
    Sagen Zac‐Varghese, Patrick Barry Mark, Steve C Bain, Debasish Banerjee, Tahseen Ahmad Chowdhury, Indranil Dasgupta, Parijat De, Damian G. Fogarty, Andrew Frankel, Gabrielle Goldet et al. · 2024 · BMC Nephrology
  24. Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease
    Wright, R. Scott, Ray, Kausik K., Landmesser, Ulf, Koenig, Wolfgang, Raal, Frederick J., Leiter, Lawrence A., Conde, Lorena Garcia, Han, Jackie, Schwartz, Gregory G. · 2024 · Mayo Clinic Proceedings
  25. Therapeutic Inertia in Dyslipidemia Management for Secondary Cardiovascular Prevention: Results from the Italian ITACARE-P Network
    Andrea Faggiano, Anna Gualeni, Lucia Barbieri, Gian Francesco Mureddu, Elio Venturini, Francesco Giallauria, Marco Ambrosetti, Matteo Ruzzolini, Francesco Maranta, Maria Vittoria Silverii et al. · 2025 · Journal of Clinical Medicine
  26. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
    Erik S.G. Stroes, Harold Edward Bays, Maciej Banach, Alberico Luigi Catapano, Paul Barton Duell, Ulrich Laufs, G.B. John Mancini, Kausik Kumar Ray, William J. Sasiela, Yang Zhang et al. · 2023 · Atherosclerosis
  27. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
    Assunta Di Costanzo, Ciro Indolfi, Sabato Sorrentino, Giovanni Esposito, Carmen Spaccarotella · 2023 · International Journal of Molecular Sciences
  28. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
    Juan Luis Tamargo, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Elisabetta Cerbai, Gheorghe Andrei Dan, Péter Ferdinándy, Erik Lerkevang Grove, Bianca Rocca, Emma Forton Magavern et al. · 2024 · European Heart Journal - Cardiovascular Pharmacotherapy
  29. Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug–Drug Interactions
    Nicola Ferri, Elisa Colombo, Alberto Corsini · 2024 · Pharmaceutics
  30. Statin use in HIV: European AIDS Clinical Society guidance for the primary prevention of cardiovascular disease
    Jasmini Alagaratnam, Kathrin van Bremen, Georg M. N. Behrens, Franck Boccara, Paola Maria Cinque, Magnus Gisslén, Giovanni Guaraldi, Déborah Konopnicki, Justyna Dominika Kowalska, Patrick W. G. Mallon et al. · 2025 · The Lancet HIV
  31. Residual lipid risk in atherosclerotic cardiovascular disease
    Børge Grønne Nordestgaard, Robert Alexander Hegele · 2026 · European Heart Journal
  32. Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management
    Iulia Iatan, G.B. John Mancini, Eunice Yeoh, Robert Alexander Hegele · 2023 · Expert Review of Cardiovascular Therapy
  33. Role of Residual Inflammation as a Risk Factor Across Cardiovascular-Kidney-Metabolic (CKM) Syndrome: Unpacking the Burden in People with Type 2 Diabetes
    Roya Ghafoury, Mojtaba Malek, Faramarz Ismail‐Beigi, Mohammad E. Khamseh · 2025 · Diabetes Therapy
  34. Statin‐associated muscle symptoms: A comprehensive exploration of epidemiology, pathophysiology, diagnosis, and clinical management strategies
    Meera Shah, Karun Shrestha, Chih‐Wei Tseng, Aman Goyal, Teerin Liewluck, Latika Gupta · 2024 · International Journal of Rheumatic Diseases
  35. Competing Risks in Clinical Trials
    John Gregson, Stuart Pocock, Stefan D. Anker, Deepak L. Bhatt, Milton Packer, Gregg W. Stone, Cordula Zeller · 2024 · Journal of the American College of Cardiology
  36. The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications
    Christie Mitchell Ballantyne, Giuseppe Danilo Norata · 2025 · European Heart Journal
  37. The Inherited Basis of Coronary Artery Disease
    Heribert Schunkert, Pradeep Natarajan, Nilesh J. Samani · 2026 · New England Journal of Medicine
  38. Bempedoic Acid: An Emerging Therapy for Uncontrolled Low-Density Lipoprotein (LDL) Cholesterol
    Akshyaya Kumar Pradhan, Monika Bhandari, Pravesh Vishwakarma, Abhishek Singh, Marco Alfonso Perrone, Rishi Sethi · 2023 · Journal of Cardiovascular Development and Disease
  39. Recent advances in regulating lipid metabolism to prevent coronary heart disease
    Jingchun Du, Wei Wu, Boran Zhu, Weiwei Tao, Lina Liu, Xiaolan Cheng, Min Zhao, Jibiao Wu, Yunlun Li, Ke Pei · 2023 · Chemistry and Physics of Lipids
  40. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice
    Lorenzo Buzzelli, Andrea Segreti, Daniela Di Gioia, Erika Lemme, Maria Rosaria Squeo, Antonio Nenna, Giuseppe Di Gioia · 2023 · Fitoterapia
  41. Dyslipidemia Treatment and Cerebrovascular Disease: Evidence Regarding the Mechanism of Stroke
    Sang Hee Ha, Bum Joon Kim · 2024 · Journal of Lipid and Atherosclerosis
  42. Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis
    Masson, Walter, Lobo, Martín, Nogueira, Juan P., Barbagelata, Leandro, Touzas, Pedro, Frías, Juan P. · 2026 · Reviews in Endocrine and Metabolic Disorders
  43. Optimal Medical Management of Atherosclerotic Intracranial Stenosis
    Ashley Wabnitz, Tanya N. Turan · 2024 · Stroke
  44. Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
    Almudena Castro Conde, Domingo Marzal Martín, Raquel Campuzano Ruíz, María Rosa Fernández Olmo, Carlos Morillas Ariño, Juan José Gómez‐Doblas, José Luis Górriz, Pilar Mazón‐Ramos, Xavier García–Moll, María José Soler et al. · 2023 · Journal of Clinical Medicine
  45. A Look to the Past - What Has Had the Biggest Impact on Lipids in the Last Four Decades? A Personal Perspective
    Maciej Banach, Stanisław Surma · 2023 · Archives of Medical Science
  46. Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
    Farzahna Mohamed, Brett Stephen Mansfield, Frederick Johan Raal · 2023 · Journal of Clinical Medicine
  47. Present and Future of Dyslipidaemia Treatment—A Review
    Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Barbić Radman, Ivan Pećin, Željko Reiner · 2023 · Journal of Clinical Medicine
  48. Unveiling Familial Hypercholesterolemia—Review, Cardiovascular Complications, Lipid-Lowering Treatment and Its Efficacy
    Piotr Fularski, Joanna Hajdys, Gabriela Majchrowicz, Magdalena Stabrawa, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2024 · International Journal of Molecular Sciences
  49. Learnings from Implementation Strategies to Improve Lipid Management
    Nick S.R. Lan, Ruofei Trophy Chen, Girish Dwivedi, Gerald Francis Watts, Stephen James Nicholls, Adam J. Nelson · 2025 · Current Cardiology Reports
  50. Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the American Geriatrics Society
    Vera Bittner, Sunny Anne Linnebur, Dave L. Dixon, Daniel E. Forman, Ariel R. Green, Terry A. Jacobson, Ariela R. Orkaby, Joseph J. Saseen, Salim S. Virani · 2025 · Journal of clinical lipidology
  51. The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials
    Sayed, Ahmed, Shazly, Omar, Slipczuk, Leandro, Krittanawong, Chayakrit, Baloch, Farhala, Virani, Salim S. · 2024 · Cardiovascular Drugs and Therapy
  52. Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies
    Catapano, Alberico L., Mikhailova, Elina, Navar, Ann Marie, Banka, Puja, Corral, Pablo, Saxena, Manish, Steg, P. Gabriel, Verma, Subodh, Kordahi, Andrew Yacoub, Mendizabal, Geraldine et al. · 2026 · JACC
  53. Metabolic dysfunction–associated steatotic liver disease, hypertriglyceridaemia, and cardiovascular risk
    Gurevitz, Chen, Rosenson, Robert S · 2024 · European Journal of Preventive Cardiology
  54. Recent advances in the management and implementation of care for familial hypercholesterolaemia
    Nick S.R. Lan, Archna Bajaj, Gerald Francis Watts, Marina Cuchel · 2023 · Pharmacological Research
  55. Quality of life in patients with statin intolerance: a multicentre prospective registry study
    Paulina Elena Stürzebecher, Ioanna Gouni‐Berthold, Christina Mateev, Ole Frenzel, Stephan Erbe, Jes‐Niels Boeckel, Markus R. Scholz, Ulrike Schatz, Oliver Weingärtner, Ursula Kassner et al. · 2024 · The Lancet Regional Health - Europe
  56. Diabetes and cardiovascular disease in older adults
    Anika Bilal, Richard E. Pratley · 2024 · Annals of the New York Academy of Sciences
  57. Genomic Innovation in Early Life Cardiovascular Disease Prevention and Treatment
    Changwei Li, Yang Pan, Ruiyuan Zhang, Zhijie Huang, Davey Li, Yunan Han, Claire T. Larkin, Varun Rao, Xiao Sun, Tanika N. Kelly · 2023 · Circulation Research
  58. Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
    Giulio Preta · 2023 · Cells
  59. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting
    Udita Gupta, Thomas M. Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan E. Gray · 2023 · The American Journal of the Medical Sciences
  60. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis
    Dinu, Monica, Sofi, Francesco, Lotti, Sofia, Colombini, Barbara, Mattioli, Anna Vittoria, Catapano, Alberico L, Casula, Manuela, Baragetti, Andrea, Wong, Nathan D, Steg, Philippe Gabriel et al. · 2024 · European Journal of Preventive Cardiology
  61. Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis
    David Mutschlechner, Maximilian Tscharre, Kurt Huber, Thomas Gremmel · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
  62. Efficacy and outcomes of Bempedoic acid versus placebo in patients with statin-intolerance: A pilot systematic review and meta-analysis of randomized controlled trials
    Aman Goyal, Mah I Kan Changez, Muhammad Daoud Tariq, Fiza Mushtaq, Urooj Shamim, Amir Humza Sohail, Gauranga Mahalwar · 2023 · Current Problems in Cardiology
  63. Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex
    Leslie Cho, Jorge Plutzky, Danielle M. Brennan, Michael J. Louie, Lei Lei, Paula L. Robinson, Heather A. Powell, Stephen James Nicholls, Abraham Michael Lincoff, Steven E. Nissen · 2024 · Circulation
  64. Strategies for chronic coronary disease: A brief guide for clinicians
    Chayakrit Krittanawong, Muzamil Khawaja, Hafeez Ul Hassan Virk, Johao Escobar, Umair Khalid, Yochai Birnbaum, Carl J. Lavie, Samin Kumar Sharma, Hani M. Jneid, Sunil V. Rao et al. · 2024 · npj Cardiovascular Health
  65. Multi-biobank Mendelian randomization analyses identify opposing pathways in plasma low-density lipoprotein-cholesterol lowering and gallstone disease
    Guoyi Yang, Amy M. Mason, Dipender Gill, Catherine Mary Schooling, Stephen Burgess · 2024 · European Journal of Epidemiology
  66. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
    Edurne Arriola, Javier de Castro, Rosario García-Campelo, Beatriz Bernárdez, Reyes Bernabé, Jordi Bruna, Manuel Dómine, Dolores Isla, Óscar Juan, Teresa López‐Fernández et al. · 2024 · Clinical Drug Investigation
  67. Reversal of Atherosclerotic Plaque Growth and Vulnerability: Effects of Lipid-Modifying and Anti-Inflammatory Therapeutic Agents
    Michail I. Papafaklis, Rafail Koros, Grigorios Tsigkas, Αντώνιος Καρανάσος, Αθανάσιος Μούλιας, Periklis A. Davlouros · 2024 · Biomedicines
  68. Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
    Tramontano, Daniele, Bini, Simone, Maiorca, Carlo, Di Costanzo, Alessia, Carosi, Martina, Castellese, Jacopo, Arizaj, Ina, Commodari, Daniela, Covino, Stella, Sansone, Giorgia et al. · 2025 · Drugs
  69. ACLY Promotes Cardiac Fibrosis via the Regulation of DNL and Histone Acetylation
    Naoya Kuwahara, Manabu Nagao, Masakazu Shinohara, Kenta Kaneshiro, Takuo Emoto, Takeshi Yoshida, Terunobu Fukuda, Makoto Nishimori, Seimi Satomi‐Kobayashi, Hiromasa Otake et al. · 2025 · Hypertension
  70. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024
    Juan Luis Tamargo, Stefan Agewall, Giuseppe Ambrosio, Claudio Borghi, Elisabetta Cerbai, Gheorghe Andrei Dan, Heinz Drexel, Péter Ferdinándy, Erik Lerkevang Grove, Roland Klingenberg et al. · 2025 · European Heart Journal - Cardiovascular Pharmacotherapy
  71. An update on renal tubular injury as related to glycolipid metabolism in diabetic kidney disease
    Anqi Feng, Ruili Yin, Rong Xu, Baoyu Zhang, Longyan Yang · 2025 · Frontiers in Pharmacology
  72. Cardiovascular Benefit of Colchicine in Relation to Baseline Risk: A Secondary Analysis of the LoDoCo2 Trial
    Niekbachsh Mohammadnia, Britta E. Wesselink, Willem A. Bax, Stefan Mark Nidorf, Arend Mosterd, Aernoud T.L. Fiolet, Aysun Cetinyurek‐Yavuz, Peter Lindsay Thompson, Shrikant I. Bangdiwala, John W. Eikelboom et al. · 2025 · Journal of the American Heart Association
  73. Revisiting the metabolic crosstalk between type 2 diabetes and hyperuricemia: Pathophysiological insights and therapeutic perspectives
    Xiuqiang Xia, Hongyu Niu, Changsong Xu, Xinghao Liu, Guoying Zhang, Jianya Ling · 2025 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  74. Optimal Medical Therapy Targeting Lipids and Inflammation for Secondary Prevention in Patients Undergoing Percutaneous Coronary Intervention
    Imma Forzano, Domenico Florimonte, Viviana Narciso, Mario Enrico Canonico, Domenico Simone Castiello, Lina Manzi, Stefano Cristiano, Alessandra Maria Spinelli, Donato Maria Vallone, Dario D’Alconzo et al. · 2025 · Journal of Clinical Medicine
  75. Lipid profile and lipoprotein(a) testing
    Klaus Georg Parhofer, Ulrich Laufs · 2023 · Deutsches Ärzteblatt international
  76. Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update
    Fabiana Lucà, Fabrizio Giovanni Oliva, Carmelo Massimiliano Rao, Maurizio Giuseppe Abrignani, Antonio Francesco Amico, Stefania Angela Di Fusco, Giorgio Caretta, Irene Di Matteo, Concetta Di Nora, Anna Pilleri et al. · 2023 · Metabolites
  77. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events
    Alberto Cordero, Rosa Fernández Olmo, Lina Badimón, Carlos G. Santos‐Gallego, Jose Maria Castellano, Lorenzo Fácila, Moisés Rodríguez‐Mañero, Clara Bonanad, Gemma Vilahur, David Escribano et al. · 2023 · Journal of clinical lipidology
  78. HDL as a Treatment Target: Should We Abandon This Idea?
    Floran Bègue, Marie Laurine Apalama, Gilles C. Lambert, Olivier Meilhac · 2023 · Current Atherosclerosis Reports
  79. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials
    Paul Barton Duell, Maciej Banach, Alberico Luigi Catapano, Ulrich Laufs, G.B. John Mancini, Kausik Kumar Ray, Christine Broestl, Yang Zhang, Lei Lei, Anne Carol Goldberg · 2024 · Journal of clinical lipidology
  80. Colchicine for the Prevention of Cardiovascular Disease: Potential Global Implementation
    Robert S. Zhang, Brittany Weber, Diego Araiza Garaygordobil, Michael Seth Garshick · 2024 · Current Cardiology Reports
  81. Management of dyslipidemia in coronary artery disease: the present and the future
    Kyriakos S. Dimitriadis, Panagiotis Theofilis, Panagιotis Iliakis, Nikolaos Pyrpyris, Eirini Dri, Athanasios Sakalidis, Στέργιος Σουλαϊδόπουλος, Panagiotis Tsioufis, Christos Fragkoulis, Christina A. Chrysohoou et al. · 2024 · Coronary Artery Disease
  82. ATP-Citrate Lyase Supports Cardiac Function and NAD+/NADH Balance and Is Depressed in Human Failing Myocardium
    Mariam Meddeb, Navid Koleini, Mohammad Keykhaei, Ting Liu, Marcus Rhodehamel, Lorena Mandarano, Farnaz Farshidfar, Liang Zhao, Seoyoung Kwon, Gizem Keceli et al. · 2025 · JACC Basic to Translational Science
  83. Bempedoic Acid: Lipid Lowering for Cardiovascular Disease Prevention
    Michael Stanley Albosta, Jelani Kayode Grant, Erin D. Michos · 2023 · Heart International
  84. Oral PCSK9 Inhibitors: Will They Work?
    Lale S Tokgözoğlu, Angela Pirillo, Alberico Luigi Catapano · 2025 · Current Atherosclerosis Reports
  85. HDL metabolism and function in diabetes mellitus
    Blake J. Cochran, Thomas W King, Kévin Chemello, Shane Ross Thomas, Kerry‐Anne Rye · 2025 · Nature Reviews Endocrinology
  86. Atherosclerotic plaque, cardiovascular risk, and lipid-lowering strategies: a narrative review
    Frankie Chor-Cheung Tam, Min-Ge Lin, Tsun-Ho Lam, Hung-Fat Tse, Chun‐Ka Wong · 2025 · Frontiers in Cardiovascular Medicine
  87. Coronary artery calcium in 2023: Guidelines for LDL-C goals, non-statin therapies, and aspirin use
    Garshasb Soroosh, Erfan Tasdighi, Rishav Adhikari, Michael Joseph Blaha · 2024 · Progress in Cardiovascular Diseases
  88. Exploring the Role of Bempedoic Acid in Metabolic Dysfunction Associated Steatotic Liver Disease: Actual Evidence and Future Perspectives
    Elena Butera, Fabrizio Termite, Giorgio Esposto, Linda Galasso, Irene Mignini, Raffaele Borriello, Maria Elena Ainora, Luca Miele, Antonio Gasbarrini, Maria Assunta Zocco · 2024 · International Journal of Molecular Sciences
  89. Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention
    Aikaterini Komnianou, Konstantinos G. Kyriakoulis, Ariadni Menti, Evangelos P. Dimakakos, George S. Stergiou, Αναστάσιος Κόλλιας · 2025 · Journal of Clinical Medicine
  90. Managing Hypercholesterolemia in Adults Older Than 75 years Without a History of Atherosclerotic Cardiovascular Disease: An Expert Clinical Consensus From the National Lipid Association and the American Geriatrics Society
    Vera Bittner, Sunny Anne Linnebur, Dave L. Dixon, Daniel E. Forman, Ariel R. Green, Terry A. Jacobson, Ariela R. Orkaby, Joseph J. Saseen, Salim S. Virani · 2025 · Journal of the American Geriatrics Society
  91. Traditional and novel non-statin lipid-lowering drugs
    Peeyush Jain · 2023 · Indian Heart Journal
  92. Management of Peripheral Artery Disease in Adults With Diabetes: 2025 ACC Scientific Statement
    Sandeep R. Das, Marc P. Bonaca, Mark A. Creager, Nisa M. Maruthur, Joakim Nordanstig, Rodica Pop‐Busui, Francisco Ujueta · 2025 · Journal of the American College of Cardiology
  93. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference
    Kartik Gupta, Isabel Balachandran, Jacob Foy, Melody Hermel, Azka Latif, Chayakrit Krittanawong, Leandro N. Slipczuk, Farhala Baloch, Zainab Z. Samad, Salim S. Virani · 2023 · Current Atherosclerosis Reports
  94. Metabolic adaptations in pressure overload hypertrophic heart
    Jinfeng Wei, Xuefei Duan, Jiaying Chen, Dengwen Zhang, Jindong Xu, Jian Zhuang, Sheng Wang · 2023 · Heart Failure Reviews
  95. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress
    Kartik Gupta, Colin Andrew Hinkamp, Tyler Q. Andrews, Chelsea Meloche, Abdul Mannan Khan Minhas, Leandro N. Slipczuk, Elizabeth M. Vaughan, Fatima Zohra Habib, Sana Sadiq Sheikh, Dinesh Kumar Kalra et al. · 2023 · Current Atherosclerosis Reports
  96. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid
    Siva Naga S. Yarrarapu, Amandeep Goyal, Vikramaditya Samala Venkata, Viraj S. Panchal, Barath Prashanth Sivasubramanian, Doantrang T. Du, Roopesh Sai Jakulla, Hema Pamulapati, Mazhar A. Afaq, Steven Owens et al. · 2024 · Journal of Cardiology
  97. Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas
    Eleni Papantoniou, Konstantinos Arvanitakis, Konstantinos Markakis, Stavros P. Papadakos, Οlga Tsachouridou, Djordje S. Popovic, Theocharis Koufakis, Georgios S. Germanidis, Kalliopi Kotsa · 2024 · Life
  98. Management of dyslipidaemia in patients with comorbidities: facing the challenge
    Gert J. Mayer, Dobromir Dobrev, Juan Carlos Kaski, Anne Grete Semb, Kurt Huber, Andreas Zirlik, Stefan Agewall, Heinz Drexel · 2024 · European Heart Journal - Cardiovascular Pharmacotherapy
  99. Closing the gap between guidelines and clinical practice for managing dyslipidemia: where are we now?
    Sohum Sheth, Maciej Banach, Peter Paul Toth · 2024 · Expert Review of Cardiovascular Therapy
  100. Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors
    Turchin, Alexander, Petito, Lucia C., Hegermiller, Emma, Carnahan, Ryan, DeVries, Andrea, Goel, Satyender, Lansang, M. Cecilia, McDonnell, Marie E., Nair, Vinit, Priest, Elisa et al. · 2025 · JAMA Network Open